Login to Your Account



A fungus among us: FDA adcom tempers Cempra, lefamulin affair starting?

By Randy Osborne
Staff Writer

Tuesday, November 15, 2016

Amesh Adalja told BioWorld Today that, although too early to tell for sure about toxicity, it’s “an encouraging sign” that Nabriva Therapeutics AG has chosen to develop lefamulin.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription